How Science, Industry and Capital Are Racing for Technological Sovereignty
Europe is approaching a strategic inflection point. While the United States dominates global software ecosystems and Asia consolidates its leadership in advanced manufacturing, the continent is rediscovering one of its historical strengths: science.
In this context, deep tech entrepreneurship is emerging as one of the most promising engines for a new wave of European industrial renewal.
Yet a paradox remains. Europe hosts some of the world’s most respected research institutions and produces an enormous volume of scientific knowledge, but much of it never reaches the market. Estimates suggest that more than 95 percent of European patents remain inactive—they never become commercial products.
The problem is not talent. The problem is not capital. The challenge is transforming knowledge into industry.
Deep Tech as Industrial Infrastructure
Deep tech is not simply another category of startup innovation. It represents a different technological paradigm.
Unlike conventional software ventures, deep tech companies are built on fundamental scientific discoveries or complex engineering breakthroughs. These ventures often involve hardware systems, advanced materials, biotechnology, or specialized manufacturing technologies.
Three characteristics define most deep tech companies:
• Tangible technology rooted in scientific research
• Long development cycles that require experimentation and validation
• Significant capital intensity during early stages
When these technologies succeed, their impact is structural. They do not merely create products—they create new industrial capabilities.
For Europe, this is particularly important. The continent remains heavily dependent on foreign digital infrastructure. More than 80 percent of cloud platforms and digital services used in Europe originate outside the region.
Deep tech offers a path toward technological autonomy by enabling Europe to build critical capabilities from its own scientific base.
The Capital Paradox in European Deep Tech
Despite increasing enthusiasm around deep tech investment, many science-based startups still struggle to secure funding.
The issue is not a shortage of money. Venture capital investment in Europe continues to grow each year. The difficulty lies elsewhere.
Many investors are comfortable analyzing commercial risk—such as market size, pricing models, or competitive positioning. Deep tech, however, introduces a different challenge: technological uncertainty.
The key question is not whether a market exists, but whether a scientific breakthrough can scale into a reliable industrial system.
This distinction matters. Risk can be priced. Uncertainty is harder to model.
As a result, some investors wait for market validation before committing capital. This cautious behavior slows down early development and often pushes promising European startups toward premature acquisitions by foreign corporations.
Ironically, long-term data suggests that deep tech funds perform well. Average net returns around 17 percent have been reported, compared with approximately 10 percent for traditional technology funds.
The Hidden Role of Europe’s RTO Network
A distinctive feature of the European innovation ecosystem is the presence of Research and Technology Organizations (RTOs).
Institutions such as Fraunhofer in Germany, CEA in France, or Tecnalia in Spain act as industrial bridges between academic research and market applications.
Across Europe, the network of RTOs includes more than 200,000 researchers and manages tens of thousands of patents. Over the past decade, these institutions have supported the creation of thousands of technology startups.
Their mission is straightforward: translate scientific knowledge into industrial capability.
Successful models combine several mechanisms:
• Spin-offs led by researchers
• Internal venture builders
• Partnerships with external startups
This hybrid model has become one of the defining strengths of the European innovation system.
Medtech and the Convergence of Science and Healthcare
Within the broader deep tech landscape, the medical technology sector is undergoing rapid transformation.
Artificial intelligence, digital sensors, robotics, and advanced diagnostics are reshaping how healthcare systems detect and treat disease.
Several trends are accelerating simultaneously:
• Personalized medicine based on predictive analytics and genomic data
• Home diagnostics and remote patient monitoring
• Surgical robotics and advanced manufacturing technologies
• Femtech and innovations focused on women’s health
However, investor expectations have changed significantly. The era of funding exciting technological ideas without validation is fading. Investors now demand clear evidence of progress.
Key signals include:
• Clinical evidence from pilot studies
• Interoperability with hospital systems through health data standards such as FHIR R4 and DICOM
• Visibility on reimbursement models within healthcare systems
Technology alone is no longer sufficient. Execution has become the defining factor.
Spain as an Emerging Deep Tech Opportunity
Within the European landscape, Spain is beginning to attract attention as a promising deep tech hub.
The country presents a structural imbalance between strong scientific capability and comparatively modest startup valuations. This creates a form of investment arbitrage.
Operating costs in Spain are significantly lower than in major European innovation centers. Launching and operating a deep tech startup can be 30 to 40 percent cheaper than in places such as Cambridge or Munich.
At the same time, Spain hosts advanced scientific infrastructure, including the ALBA Synchrotron, the Barcelona Supercomputing Center, and national initiatives in quantum computing.
Catalonia, in particular, has emerged as a powerful life sciences cluster. The BioRegion of Catalonia now generates more than €48 billion in economic activity and represents over 7 percent of the region’s GDP.
Investment is beginning to reflect this momentum.
The Role of Public Capital
Deep tech ventures require long development cycles before they can attract significant private investment.
Public funding, therefore, plays a critical role during the early stages of technological validation.
European programs such as the EIC Accelerator combine grants of up to €2.5 million with equity investments of up to €15 million. These instruments support technologies approaching commercial readiness.
In Spain, national initiatives such as NEOTEC programs from CDTI and co-investment vehicles have also become essential tools.
Large corporations are increasingly participating through corporate venture activity. Companies including Medtronic, Johnson & Johnson, and Philips invest directly in startups to secure access to emerging technologies.
Structural Challenges Ahead
Despite positive momentum, the European deep tech ecosystem faces several structural challenges.
Cybersecurity is becoming a major concern. Studies suggest that more than half of connected medical devices contain known vulnerabilities. Regulatory frameworks increasingly require robust vulnerability management and software bill of materials documentation.
Another challenge lies in entrepreneurial talent. Many science-driven startups lack experienced commercial leaders capable of navigating regulatory approval, market access, and global scaling.
Capital fragmentation also remains an issue. In several regions, including Spain, there are still relatively few funds capable of leading large Series B rounds or later-stage growth investments.
Finally, regulatory complexity continues to slow down innovation. Medical device approvals under European MDR frameworks or U.S. FDA processes may require three to seven years and significant financial resources.
A New Compact Between Science, Industry, and Capital
If Europe intends to fully unlock its deep tech potential, a new alignment between science, industry, and capital will be necessary.
Scientific institutions generate knowledge. Industrial partners scale technologies. Capital absorbs technological uncertainty.
The most successful deep tech startups will be those that combine these three forces into coherent execution.
Europe already possesses the raw ingredients. The challenge now is coordination.
The Strategic Decade Ahead
The next decade will determine Europe’s role in the global technology landscape.
Pure software innovation will not be enough. The frontier is shifting toward the intersection of science, engineering, and industry.
In that environment, deep tech may become one of the most powerful engines for Europe’s industrial renewal.
The question is no longer whether the continent can produce breakthrough science.
The question is whether it can build industries from it.
